TOKYO

东京

,

，

May 26, 2026

2026年5月26日

/PRNewswire/ --

/PRNewswire/ --

Olympus Corporation

奥林巴斯公司

(Olympus), a global MedTech company committed to advancing endoscopy-enabled care, announced today it has signed a definitive agreement to acquire BioProtect Ltd. (BioProtect), a medical device manufacturer aiming to advance cancer care through innovative spacing solutions. This marks an important expansion of Olympus' contributions to oncology and urology in line with its corporate strategy to accelerate cutting-edge technologies and focus on patient safety and outcomes.

奥林巴斯（Olympus）是一家致力于推进内窥镜诊疗的全球医疗技术公司，今天宣布已签署最终协议，收购生物保护有限公司（BioProtect Ltd.，简称BioProtect）。BioProtect是一家医疗设备制造商，致力于通过创新的间隔解决方案改善癌症治疗。这标志着奥林巴斯在加速前沿技术和关注患者安全与疗效的公司战略下，在肿瘤学和泌尿外科领域的重要扩展。

The $270 million acquisition, with certain amounts held in escrow for a period dependent on uninterrupted operation of the business, is expected to be completed by the end of the second quarter of calendar year 2026, subject to customary closing conditions..

这笔 2.7 亿美元的收购交易预计将在 2026 年日历年第二季度末完成，部分金额将根据业务的不间断运营情况在一定时间内存入托管账户，具体完成时间取决于惯例的交割条件。

Continue Reading

继续阅读

BioProtect Balloon Spacer

BioProtect气球间隔器

BioProtect develops implant technologies that contribute to improving prostate cancer care and enhancing patients' quality of life. Its flagship Balloon Spacer system is designed to provide consistent spacing between the prostate and other critical structures, protecting healthy tissues during prostate cancer radiation therapies.

BioProtect 开发了有助于改善前列腺癌治疗并提高患者生活质量的植入技术。其旗舰产品Balloon Spacer系统旨在提供前列腺与其他关键结构之间的一致间距，在前列腺癌放射治疗期间保护健康组织。

After treatment, the implant naturally biodegrades. Following its commercial introduction in 2023, the Balloon Spacer has been used in more than 11,000 procedures worldwide, with studies indicating the device's contribution to preserving gastrointestinal, urinary and sexual functions for patients..

治疗后，植入物自然生物降解。自2023年商业推出以来，Balloon Spacer 已在全球超过11,000例手术中使用，研究表明该装置有助于保留患者的胃肠、泌尿和性功能。

1,2

1,2

For Olympus, the acquisition of BioProtect aligns with its strategic pillar of

对于奥林巴斯来说，收购BioProtect与其战略支柱相符。

Innovation-driven Growth

创新驱动增长

as a global MedTech leader. With prostate cancer as the second most diagnosed form of cancer amongst men worldwide, the acquisition underscores the company's commitment to solutions that address unmet medical needs in cancer treatment. An estimated 1.5 million patients are diagnosed with prostate cancer annually, and the global rectal spacer market is projected to experience strong growth over the next 10 years.

作为全球医疗技术领域的领导者，前列腺癌是世界范围内男性中第二常见的癌症类型，此次收购凸显了该公司致力于解决癌症治疗中未满足的医疗需求的承诺。据统计，每年约有150万患者被诊断出患有前列腺癌，而全球直肠间隔器市场预计在未来十年内将实现强劲增长。

The transaction helps Olympus expand its portfolio in adjacent therapeutic areas related to endoscopy, including the gastrointestinal and urological fields, and enhance its value proposition across the entire care pathway..

该交易有助于奥林巴斯扩展其在与内窥镜相关的相邻治疗领域（包括胃肠道和泌尿科领域）的产品组合，并提升其在整个护理路径中的价值主张。

'We are pleased to welcome BioProtect to Olympus,' said Seiji Kuramoto, Executive Officer and Surgical and Interventional Solutions Division Head at Olympus. 'BioProtect brings a highly differentiated solution to prostate cancer care, with a compelling clinical value proposition and early commercial success.

“我们很高兴欢迎BioProtect加入奥林巴斯，”奥林巴斯执行官兼外科与介入解决方案部门负责人Seiji Kuramoto表示。“BioProtect为前列腺癌治疗带来了高度差异化的解决方案，具有令人信服的临床价值主张和早期商业成功。”

By combining BioProtect's strengths with Olympus' global reach and relationships with healthcare professionals, we believe we can expand access to solutions that support better patient outcomes and help clinicians to advance the treatment of prostate cancer.'.

通过将BioProtect的优势与奥林巴斯的全球影响力及与医疗专业人员的关系相结合，我们相信可以扩大获得支持更好患者预后的解决方案的机会，并帮助临床医生推进前列腺癌的治疗。

'BioProtect is extremely excited to join Olympus as a key part of the company's continued expansion into urology and oncology,' said Itay Barnea, Chief Executive Officer of BioProtect. 'We look forward to integrating our differentiated spacing technology into the overall portfolio of Olympus. This represents a significant advancement for BioProtect, our physician partners and ultimately the patients we serve, combining innovative technology, clinical excellence and commercial scale to expand access to high-quality care for men undergoing treatment for prostate cancer.' .

“BioProtect非常高兴能作为关键部分加入奥林巴斯，成为公司持续扩展泌尿科和肿瘤科的一部分，”BioProtect首席执行官Itay Barnea表示。“我们期待将我们差异化的间隔技术整合到奥林巴斯的整体产品组合中。这对BioProtect、我们的医生合作伙伴以及最终我们服务的患者而言，是一项重要的进步，结合了创新技术、临床卓越和商业规模，扩大了接受前列腺癌治疗的男性获得高质量护理的机会。”

1 Song, Daniel et al.: Long-Term Toxicity and Patient-Reported Quality of Life after Prostate IMRT With or Without Biodegradable Balloon Rectal Spacer: Analysis of a Pivotal Randomized Trial.

1 宋，丹尼尔等：前列腺IMRT联合或不联合可生物降解球囊直肠间隔物的长期毒性和患者报告的生活质量：一项关键随机试验的分析。

ASTRO 2025 Conference Abstract, unpublished.

ASTRO 2025 会议摘要，未发表。

2 Cloitre, Minna et al.: Toxicity, Quality of Life, and PSA Control After 50 Gy Stereotactic Body Radiation Therapy to the Dominant Intraprostatic Nodule With the Use of a Rectal Spacer: Results of a Phase I/II Study.

2 Cloitre, Minna 等：使用直肠间隔物对前列腺内主要结节进行50 Gy立体定向体部放射治疗后的毒性、生活质量及PSA控制：I/II期研究结果。

British Journal of Radiology 2023 Apr 1;96(1145):20220803. doi: 10.1259/bjr.20220803.

英国放射学杂志 2023年4月1日；96（1145）：20220803。doi: 10.1259/bjr.20220803。

About BioProtect

关于BioProtect

Established in 2004 and headquartered in Israel, BioProtect is a medical device manufacturer with a mission to empower healthcare providers with its innovative biodegradable rectal spacer balloon product, elevating prostate cancer care and enhancing patient quality of life. With revenue of approximately $14.5 million in 2025, the company has 130 employees..

成立于2004年，总部位于以色列，BioProtect是一家医疗设备制造商，其使命是通过创新的可生物降解直肠间隔球囊产品，为医疗服务提供者提供支持，提升前列腺癌护理水平并改善患者生活质量。公司预计2025年收入约为1450万美元，拥有130名员工。

About Olympus

关于奥林巴斯

At Olympus, we are committed to Our Purpose of making people's lives healthier, safer and more fulfilling. As a global medical technology company, we partner with healthcare professionals to provide innovative solutions and services for early detection, diagnosis and minimally invasive treatment, aiming to improve patient outcomes by elevating the standard of care in targeted disease states.

在奥林巴斯，我们致力于实现让人们的健康、安全和生活更加充实的使命。作为一家全球医疗技术公司，我们与医疗专业人士合作，提供创新的解决方案和服务，用于早期检测、诊断和微创治疗，旨在通过提升目标疾病状态下的护理标准来改善患者的治疗效果。

For more than 100 years, Olympus has pursued a goal of contributing to society by producing products designed with the purpose of delivering optimal outcomes for its customers around the world. For more information, visit the .

一个多世纪以来，奥林巴斯一直致力于通过生产旨在为全球客户提供最佳结果的产品来为社会做出贡献。欲了解更多信息，请访问网站。

Olympus website

奥林匹斯官网

and follow the

跟随

Olympus LinkedIn account

奥林匹斯领英账号

.

。

All trademarks, logos and brand names are the property of their respective owners.

所有商标、标志和品牌名称均为其各自所有者的财产。

SOURCE Olympus Corporation

来源：奥林巴斯公司

21

21

%

%

more press release views with

更多新闻发布视图与

Request a Demo

请求演示